ClinTec International celebrates further global expansion and long service awards in clinical excellence
Company on track to deliver its 25% revenue growth target for this year.
ClinTec International celebrated its exceptional year of international growth with Glasgow’s Lord Provost, guests, Country Managers and Directors from over 40 countries, at the ClinTec International Global Conference held in Glasgow last week. Attended by ClinTec International staff and The Right Honourable Lord Provost of Glasgow, Sadie Docherty, the 4-day event celebrated Excellence in Clinical Research Long Service Awards.
ClinTec International is a success story for British business and has recently been recognised as the “UK’s Best Full Service Clinical Research Organisation” at the Healthcare & Pharmaceuticals Awards 2015, organised by Global Health & Pharma. This sits alongside the previously received Queens Award for Enterprise and the 2015 Business Woman of the Year at the Glasgow Business Awards. Commenting on ClinTec International’s growth, the Lord Provost said “ClinTec International has had an exceptional year of growth and they are a great asset to the UK business sector. These awards show the diversity and quality of the team, which has grown together to develop the global business ClinTec International is today.”
ClinTec International is dedicated to nurturing its employees giving them the opportunity to express their talents and capabilities. Building strong teams and promoting group work, along with open minded, individual thinking was always one of the priorities for ClinTec International. The company fosters an open communication culture at all levels without any discriminations, giving the opportunity for everyone to express their opinion.
Bobby Bal, Chief Business Officer said, “This has been an amazing year for us as ClinTec International has expanded its operations into over 50 countries. ClinTec International now has new entities in Japan, Canada, South Korea, New Zealand and Hong Kong. This success lies with our people and their amazing dedication. At ClinTec International we are committed to developing our employees and we are convinced that our employees are our greatest asset. ClinTec International employees work in several international project teams and contribute towards delivering excellence to our clients, who include 7 of the top 10 pharmaceutical and leading biotech companies.”
Founded in 1997 by the Entrepreneur Dr Rabinder Buttar, ClinTec International now operates in over 50 countries. This exceptional growth is continuing as the company is on track to deliver its 25% revenue growth target for this year.
Dr Rabinder Buttar said, “Our people are our greatest asset as we continue to deliver quality global clinical solutions in our fast, flexible and focused way. With our clients, we continue to align ourselves with their needs to deliver exceptional outcomes, which is due to the strength of our team as they innovate and build. Our Global Management Conference is a celebration of what we have achieved, our cultural values and a reminder of what has made us successful. Keeping this balanced view will continue to guide us as ClinTec International continues to deliver fantastic results and sustained organic growth.”
A key step in ClinTec International’s recent African expansion has been the opening of the new office in Johannesburg. This strategic development is allowing ClinTec International to offer enhanced personalised service delivery across Africa. Presentation of the Corporate Achievement Award, won by ClinTec International at the recent African Achievement Awards for its efforts in helping to develop business and achieve growth within Africa was performed at the ClinTec International Global Conference. Beltus Etchu, Chair of African Forum Scotland, said, “This is a most exciting and opportune time for dynamic companies to be active in the African continent. ClinTec International has demonstrated both the insight and foresight to prepare themselves to capture this window of opportunity. They have made marvellous strides in pursuing their ethical and totally professional approach to growing their clinical research business in South Africa, Malawi and now into Kenya. We look forward in the coming years, to assisting ClinTec International further grow into Central and Western Sub-Saharan Africa.’’
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.